112 results on '"Heckman, Caroline A."'
Search Results
2. Genetic and functional analysis of Raynaud’s syndrome implicates loci in vasculature and immunity
3. Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia
4. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
5. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia
6. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
7. Immunogenomic Landscape of Hematological Malignancies
8. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia
9. A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow
10. Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma
11. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML
12. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia
13. Enabling the Implementation of Next-Generation Sequencing into Clinical Diagnosis: Nemhesys Project
14. Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax
15. Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML
16. Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia
17. Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance
18. Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia
19. Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients
20. Immunogenomic Landscape of Hematological Malignancies
21. Label-Free High Dimensional Single Cell Morphological Profiling of Different Hematological Malignancies By Ghost Cytometry
22. Targeting Venetoclax Resistance in TP53-Mutated Acute Myeloid Leukemia
23. The Impact of the Peptide Drug Conjugate Melflufen on the Myeloma Tumour Microenvironment
24. Combined Single Cell Flow Cytometry and Imaging Analyses Reveal Immunomodulatory Effects Exerted By Targeted Phospho-SYK Inhibitors with Elevated Sensitivity in NPM1 Mutated AML
25. Indicators of Response to the Wee1 Inhibitor Adavosertib in Acute Myeloid Leukemia
26. The XPO1-FOXC1-HOX Functional Axis Opens New Therapeutic Avenues to Treat DEK-NUP214 AML Patients
27. P-374 Stratifying multiple myeloma patients for personalized therapy based on TP53 mutation, deletion, and drug response profiles
28. A menin-KMT2A inhibitor to overcome resistance
29. Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization
30. A Potential Role of NK Cells and ABCB9 in Modulating the Response to Melflufen in Multiple Myeloma
31. The Novel Peptide Drug Conjugate OPDC3 Is Highly Active in Different Hematological Malignancies
32. P-104: Multi-omics data integration reveals molecular targets of carfilzomib resistance in multiple myeloma
33. 3094 – INHIBITION OF CKS1-DEPENDENT PROTEOSTASIS REVEALS VULNERABILITIES IN LEUKAEMIC STEM CELLS WITH CONCOMITANT PROTECTION OF HEALTHY HAEMATOPOIESIS
34. Allele-specific analysis of transcription factors binding to promoter regions
35. Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation
36. Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study
37. Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds
38. Phosphoproteomic Analysis of Primary Myeloma Patient Samples Identifies Distinct Phosphorylation Signatures Correlating with Chemo-Sensitivity Profiles in an Ex Vivo Drug Sensitivity Testing Platform
39. Deep Immune Profiling in Multiple Myeloma at Diagnosis and Under Lenalidomide Maintenance Therapy
40. Single Cell RNA Sequencing Identifies Potential Molecular Indicators of Response to Melflufen in Multiple Myeloma
41. Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database
42. Ex Vivo Drug Sensitivity Testing to Predict Response to Venetoclax + Azacitidine in Acute Myeloid Leukemia: Interim Results of the Prospective Multicenter Phase II Venex Trial
43. P-067: High dimensional CyTOF analysis of the immune system of multiple myeloma patients with different responses to lenalidomide maintenance
44. A-Myb Up-regulates Bcl-2 through a Cdx Binding Site in t(14;18) Lymphoma Cells
45. Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients
46. Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia
47. 3025 – AZACITIDINE INDUCES THROMBOCYTOPENIA VIA INHIBITION OF MEGAKARYOPOIESIS
48. In Vitro and in Vivo Activity of Melflufen in Amyloidosis
49. Associations between Microrna Expression, Disease Progression and Ex Vivo Drug Response in Multiple Myeloma
50. BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.